Estrogen decreases corpus striatal neurotoxicity in response to 6- hydroxydopamine

Brain Research

Volumn 767, Issue 2, 1997, Pages 340-344

  Dluzen, Dean ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Dihydroxyphenylacetic acid; Dopamine; Neuroprotection; Nigrostriatal; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; ESTRADIOL; ESTROGEN; NEUROPROTECTIVE AGENT; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DRUG IMPLANT; ESTROGEN THERAPY; FEMALE; HYPOPHYSIS; INTRACEREBRAL DRUG ADMINISTRATION; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OVARIECTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE PREPARATION; UTERUS WEIGHT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; ESTRADIOL; FEMALE; NEUROTOXINS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030756621     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00630-6     Document Type: Article

References (28)

1. Becker J.B. Direct effect of 17-β estradiol on striatum: Sex differences in dopamine release. Synapse. 5:1990;157-164.
2. Becker J.B., Beer M.E. The influence of estrogen on nigrostriatal dopamine activity: Behavioral and neurochemical evidence for both pre- and post-synaptic components. Behav. Brain Res. 19:1986;27-33.
3. Bedard P.J., Langelier P., Villeneuve A. Oestrogens and extrapyramidal system. Lancet. ii:1977;1367-1368.
4. Bitar M.S., Ota M., Linnoila M., Shapiro B.H. Modification of gonadectomy-induced increases in brain monoamine metabolism by steroid hormones in male and female rats. Psychoneuroendocrinology. 16:1991;547-557.
5. DeGroot J. The rat forebrain in stereotaxic coordinates. Verh. K. Ned. Acad. Wet [B]. 2:1959;1.
6. Diamond S.G., Markham C.H., Hoehn M.M., McDowell F.H., Meunter M.D. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology. 40:1990;763-766.
7. Di Paolo T., Rouillard C., Bedard P. 17-β estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur. J. Pharmacol. 117:1985;197-203.
8. K.A. Disshon, D.E. Dluzen, Estrogen as a neuromodulator of MPTP-induced neurotoxicity: Effects upon corpus striatal dopamine release. Brain Res. (1997) in press.
9. Dluzen D.E. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system in male C57/Bl mice. Brain Res. 715:1996;113-118.
10. Dluzen D.E., McDermott J.L., Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal concentrations and release. J. Neurochem. 66:1996;658-666.
11. Dluzen D.E., McDermott J.L., Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/BL mice. Neurotox. Teratol. 18:1996;603-606.
12. Dupont A.T., Di Paolo T., Gagne B., Barden N. Effects of chronic estrogen treatment on dopamine concentrations and turnover in discrete brain nuclei of ovariectomized rats. Neurosci. Lett. 22:1981;69-74.
13. Fernandez-Ruiz J.J., Amor J.C., Ramos J.A. Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2-receptors. Brain Res. 476:1989;388-395.
14. Fink G. Feedback actions of targeted hormones on hypothalamic and pituitary, with special reference to gonadal steroids. Ann. Rev. Physiol. 41:1979;571-586.
15. Gerlach M., Riederer P. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103:1996;987-1041.
16. Glazer W.M., Naftolin F., Moore D.C., Bowers M.B., MacLusky N.J. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women. Psychoneuroendocrinology. 8:1983;429-443.
17. Gordon J.H. Modulation of apomorphine-induced stereotypy by estrogen: Time course and dose response. Brain Res. Bull. 5:1980;679-682.
18. Hruska R.E. Elevation of striatal dopamine receptors by estrogen: Dose and time studies. J. Nerochem. 47:1986;1908-1915.
19. Levesque D., Di Paolo T. Rapid conversion of high to low striatal D2-dopamine receptor agonist binding states after an acute physiological dose of 17β-estradiol. Neurosci. Lett. 88:1988;113-118.
20. McDermott J.L. Effects of estrogen upon dopamine release from the corpus striatum of young and aged rats. Brain Res. 606:1993;118-125.
21. McDermott J.L., Liu B., Dluzen D.E. Sex differences and effects of estrogen on dopamine and DOPAC release from the corpus striatum of male and female CD-1 mice. Exp. Neurol. 125:1994;306-311.
22. McEwen B.S. Binding and metabolism if sex steroids by the hypothalamus-pituitary unit: physiological implications. Annu. Rev. Physiol. 42:1980;97-110.
23. Michel M.C., Rother A., Hiemke C., Ghraf R. Inhibition of synaptosomal high affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochem. Pharmacol. 36:1987;3175-3180.
24. Morissette M., Biron D., Di Paolo T. Effect of estradiol and progesterone on rat striatal dopamine uptake sites. Brain Res. Bull. 25:1990;419-422.
25. Morissette M., Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J. Neurochem. 60:1993;1876-1883.
26. Morissette M., Levesque D., Belanger A., Di Paolo T. A physiological dose of estradiol and progesterone affects striatum biogenic amines. Can. J. Physiol. Pharmacol. 68:1990;1520-1526.
27. V.D. Ramirez, Hormones and striatal dopamine activity: A novel neuroendocrine model, in: A.S. Bhatnagar (Ed.), The Anterior Pituitary Gland, Raven, New York, 1983, pp. 97-105.
28. van Hartesveldt C., Joyce J.N. Effect of estrogen on the basal ganglia. Neurosci. Biobehav. Rev. 10:1986;1-14.